Jim Cramer's Mad Dash: Celgene and Morgan Stanley Still Have Upside

NEW YORK (TheStreet) -- Shares of Celgene (CELG) are higher on Wednesday, after posting positive gains on Tuesday when many other stocks saw losses. Jim Cramer attributed these gains to the Food and Drug Administration's approval of the company's psoriasis treatment, which occurred Tuesday. 

On CNBC's "Cramer's Mad Dash" segment, Cramer, the co-manager of the Action Alerts PLUS portfolio, added that the company's work in treating breast cancer and pancreatic cancer is also a positive. 

The company could also emerge with an important arthritis treatment in the future, and "Celgene is not done going higher," he said. 

Turning to Morgan Stanley (MS) , the stock was downgraded by J.P. Morgan. The analyst suggests that the stock is expensive and that UBS AG (UBS) is more attractive. 

Cramer disagreed with the call, saying he likes Morgan Stanley. The company has a "great business" and the stock still has upside, he concluded.

 

-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Throwback Thursday: Intel Edition

Throwback Thursday: Intel Edition

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

Wednesday Wrap-Up: GE and Facebook

Wednesday Wrap-Up: GE and Facebook